SSKN · STRATA Skin Sciences, Inc.
$0.01
+0.00 (+10.00%)
At close · Jul 27
Going-concern doubt
— flagged Mar 26, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our history of operating losses and current default on our long-term debt raise substantial doubt regarding our ability to continue as a going concern.”View the 10-K filed Mar 26, 2026
Market Cap
$32,385
Shares
5.89M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Matt Hill | CFO | $302,591 |
| Dr. Dolev Rafaeli | CEO | $282,724 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Dr. Dolev Rafaeli | CEO | $593,330 |
| Matthew Hill | CFO | $476,841 |
| Matt Hill | CFO | $317,229 |
| Chris Lesovitz | CFO | — |
| Robert Moccia | CEO | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Dr. Dolev Rafaeli | CEO | $1,167,630 |
| Matthew Hill | CFO | $638,537 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Dr. Dolev Rafaeli | CEO | $2,692,066 |
| Matthew Hill | CFO | $417,846 |